# Sustained release excipients Market

> Sustained Release Excipients Market Research Report Information By Product Type (Gelatin, Polymers, Minerals, Sugars, and Others), By Route of Administration (Oral, Intramuscular, Subcutaneous, Transdermal, Intravenous, and Others), By Technology (Targeted Delivery, Microencapsulation, Wurster Technique, and Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.0%
- **2024:** $ 1.5 Billion
- **2025:** $ 1.62 Billion
- **2035:** $ 3.5 Billion
- **Key Players:** BASF SE (DE), Evonik Industries AG (DE), Ashland Global Holdings Inc. (US), Dow Inc. (US), JRS Pharma (DE), Colorcon Inc. (US), FMC Corporation (US), Gattefossé (FR), Merck KGaA (DE), Shin-Etsu Chemical Co., Ltd. (JP)

**Report ID:** MRFR/HC/20477-HCR · **Pages:** 128 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/sustained-release-excipients-market-22077

---

## Market Summary

## **Sustained Release Excipients Market Overview**

Sustained Release Excipients Market Size was valued at USD 1.4 Billion in 2023. The sustained release excipients market industry is projected to grow from USD 1.5 Billion in 2024 to USD 2.5 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.00% during the forecast period (2024 - 2032). Market drivers include the rising frequency of patent expirations and the increased need for dosage forms for the pediatric and geriatric populations, which have had a significant impact on the sustained release excipients market expansion.

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

## **Sustained Release Excipients Market Trends**

The market CAGR for sustained release excipients is expected to grow in the future due to the increasing incidence of both acute and chronic diseases. Diseases are classified into two main categories based on their duration and progression - acute and chronic diseases or such prolonged periods. Acute diseases are usually characterized by rapid onset of severe but transient symptoms. The duration of these illnesses is usually short—hours, days, or weeks—and they arise suddenly. Adjuvants with long-lasting diuretics are often used to treat acute and chronic problems.

These features increase sales of adjuvants that maintain consistency, even maintain dosage levels, reduce side effects, and promote patient adherence and disease management well. NCD) Most deaths—approximately 17.9 million annually—are due to cardiovascular diseases, followed by chronic respiratory diseases (4.1 million), diabetes (2 million, including diabetic kidney disease), and cancer (9.3 million) by October 2022. U.S.-based A statement by the Pan American Health Organization, an international public health organization, documented that 10.6 million individuals will be infected with tuberculosis (TB) by 2021, up 4.5% from 2020.

Thus, there is a market for extracted support that has a long history of severe and chronic increases due to mounting problems.

Going forward, the market for sustained release excipients is anticipated to rise at a rapid pace due to the increasing need for personalized medication. Medical practitioners use precision medicine to deliver and plan individualized care by analyzing each patient's distinct genes, proteins, and other body parts. This approach is known as personalized medicine or personalized care. Sustained-release excipients are essential to personalized medicine because they make it possible to create medication formulations that are specific to each patient's needs.

For instance, about one-third of all newly authorized therapeutic molecular entities were approved by the US Food and Drug Administration (FDA) in 2022, with 12 of those medications being personalized. Based on a paper from the US-based professional membership organization Personalized Medicine Coalition titled The Scope and Significance of Progress in 2022, this information has been compiled. Thus, the market for sustained release excipients is expanding due to the rising need for individualized treatment. Thus, driving the sustained release excipients market revenue.

## **Sustained Release Excipients Market Segment Insights**

### **Sustained Release Excipients Product Type Insights**

The Sustained Release Excipients Market segmentation, based on product type, includes Gelatin, Polymers, Minerals, Sugars, and Others. In 2023, the polymer segment dominated the market due to their versatility and fit for a range of pharmaceutical formulations. Polymers facilitate controlled drug release by forming a matrix that regulates the release of active ingredients. Because of their versatility, they are a preferred choice for sustained-release medicine delivery systems. Furthermore, polymers are still used in pharmaceuticals since longer half-lives and longer releases are needed for medications, especially for chronic illnesses.

### **Sustained Release Excipients Route of Administration Insights**

The Sustained Release Excipients Market segmentation, based on route of administration, includes Oral, Intramuscular, Subcutaneous, Transdermal, Intravenous, and Others. The oral category generated the most income in 2023. It is the most sensible and preferred way to provide medicine. The availability of the largest active surface area for drug absorption in comparison to alternative drug delivery technologies is a significant factor in the high share. The ease with which tablets and capsules can be produced has contributed significantly to the long-standing use of the oral route of medication delivery.

### **Sustained Release Excipients Technology Insights**

The Sustained Release Excipients Market segmentation, based on technology, includes Targeted Delivery, Microencapsulation, Wurster Technique, and Others. The targeted delivery category generated the most income in 2023. By delivering the medication to a desired location of action, targeted delivery lowers the possibility of drug toxicity by keeping the medication from entering unwanted bodily areas. Sustained release drug delivery systems achieve higher patient compliance, and localized drug distribution using targeted drug delivery technology leads to a consistent drug impact, less variation in drug levels in circulation, and a low chance of side effects.

**Figure 1: Sustained Release Excipients Market, by Technology, 2023 & 2032 (USD Billion)**

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

### **Sustained Release Excipients Regional Insights**

By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American sustained release excipients market area will dominate this market. Increased R&D efforts and the presence of significant pharmaceutical businesses in the area are credited with the region's success. Over the course of the forecast period, the region is expected to become more profitable due to patent expirations and the subsequent arrival of generics.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 2: SUSTAINED RELEASE EXCIPIENTS MARKET SHARE BY REGION 2023 (USD Billion)**

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

Europe sustained release excipients market accounts for the second-largest market share. The primary driver of market expansion is the aging population. Furthermore, it is projected that the advancement of complex biologics and the growing need for novel drug delivery systems will drive market growth in this sector. Further, the German sustained release excipients market held the largest market share, and the UK sustained release excipients market was the fastest growing market in the European region.

The Asia-Pacific Sustained Release Excipients Market is expected to grow at the fastest CAGR from 2024 to 2032. The increased incidence of numerous infectious diseases, the quickly expanding healthcare system, and the growing need for highly potent medications are all factors contributing to this region's rise. Moreover, China’s sustained release excipients market held the largest market share, and the Indian sustained release excipients market was the fastest growing market in the Asia-Pacific region.

### **Sustained Release Excipients Key Market Players & Competitive Insights**

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the sustained release excipients market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the sustained release excipients industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global sustained release excipients industry to benefit clients and increase the market sector. In recent years, the sustained release excipients industry has offered some of the most significant advantages to medicine. Major players in the sustained release excipients market are attempting to increase market demand by investing in research and development operations, including Allergan PLC, AstraZeneca, GlaxoSmithKline PLC, Mayne Pharma Group Limited, Mylan NV, Novartis AG, Pfizer Inc., Salix Pharmaceuticals, and Sun Pharmaceutical Industries Ltd.

As a division of AbbVie Inc., Allergan Ltd. (Allergan) is a specialty pharmaceutical business that creates and distributes over-the-counter (OTC) and branded medications as well as biosimilars. The company sells goods in the following therapeutic categories: anti-infective, urology, women's health, dermatology, central nervous system, eye care, and gastroenterology. Its clients include mail-order merchants, hospitals, clinics, government agencies, and managed healthcare providers, including health maintenance organizations and other institutions. It also distributes its products to retailers, drug wholesalers, and distributors, including national retail medicine and grocery store chains.

Biopharmaceuticals are discovered, developed, produced, and marketed by Pfizer Inc. (Pfizer). The company offers solutions to address a variety of conditions, such as those related to women's health, cancer, inflammatory diseases, immune system issues, and metabolic, cardiovascular, and pain disorders. Additionally provided are sterile injectable drugs, biosimilars, contract manufacturing services, and active pharmaceutical ingredients (APIs). For over $6.7 billion, US-based pharmaceutical and biotechnology company Pfizer Inc. purchased Arena Pharmaceuticals in December 2021.

The purchase of Arena bolsters Pfizer's capabilities and expertise in immunology and inflammation, a Pfizer innovation engine that develops effective therapies for patients with debilitating immuno-inflammatory diseases in need of new treatment options.

**Key companies in the sustained release excipients market include**

### Sustained Release Excipients Market Industry Developments

- **Q2 2024: Colorcon Expands Manufacturing Capacity in India to Meet Growing Demand for Pharmaceutical Excipients** Colorcon announced the opening of a new manufacturing facility in India to increase production of pharmaceutical excipients, including those used in sustained release formulations, to support growing demand in Asia and globally.
- **Q1 2024: Lubrizol Life Science Health Launches New Sustained Release Excipient for Oral Solid Dose Formulations** Lubrizol Life Science Health introduced a new excipient designed for sustained release oral solid dose pharmaceuticals, expanding its product portfolio for controlled drug delivery applications.
- **Q2 2024: Ashland Receives FDA Approval for New Sustained Release Excipient in Extended-Release Tablets** Ashland announced that the U.S. FDA approved its latest sustained release excipient for use in extended-release tablet formulations, marking a regulatory milestone for the company.
- **Q3 2024: BASF Partners with Indian Pharma Firm to Develop Next-Generation Sustained Release Excipients** BASF entered into a partnership with an Indian pharmaceutical manufacturer to co-develop and commercialize new sustained release excipients for advanced drug delivery systems.
- **Q2 2024: Evonik Opens New Production Line for Sustained Release Excipients in Germany** Evonik inaugurated a new production line at its German facility dedicated to manufacturing excipients for sustained release drug formulations, aiming to meet rising demand in Europe.
- **Q1 2025: Roquette Appoints New Head of Global Pharmaceutical Excipients Division** Roquette announced the appointment of a new executive to lead its global pharmaceutical excipients division, with a focus on expanding the company’s sustained release excipient offerings.
- **Q2 2025: DuPont Acquires Specialty Excipients Business from Smaller European Firm** DuPont completed the acquisition of a European specialty excipients business, strengthening its portfolio in sustained release and controlled release excipient technologies.
- **Q3 2024: DFE Pharma Launches New Co-Processed Excipient for Sustained Release Tablets** DFE Pharma introduced a new co-processed excipient specifically engineered for use in sustained release tablet formulations, targeting improved performance and manufacturability.
- **Q1 2024: Gattefossé Announces Strategic Partnership with US Biotech for Sustained Release Drug Delivery** Gattefossé entered a strategic partnership with a US-based biotech company to jointly develop lipid-based excipients for sustained release drug delivery applications.
- **Q2 2025: Lonza Invests $50 Million to Expand Excipients Manufacturing for Controlled Release Drugs** Lonza announced a $50 million investment to expand its excipients manufacturing capacity, with a focus on ingredients used in controlled and sustained release pharmaceutical products.
- **Q1 2025: Merck KGaA Launches New Polymer Excipient for Extended-Release Oral Formulations** Merck KGaA introduced a new polymer excipient designed for use in extended-release oral drug formulations, enhancing its offerings in the sustained release excipients market.
- **Q3 2025: Shin-Etsu Chemical Expands Production Capacity for Hydroxypropyl Methylcellulose Used in Sustained Release Tablets** Shin-Etsu Chemical announced the expansion of its production capacity for hydroxypropyl methylcellulose, a key excipient in sustained release tablet manufacturing, to meet increasing global demand.

## **Sustained Release Excipients Market Segmentation**

### **Sustained Release Excipients Product Type Outlook**

### **Sustained Release Excipients Route of Administration Outlook**

### **Sustained Release Excipients Technology Outlook**

### **Sustained Release Excipients Regional Outlook**

## Market Drivers

### Increasing Prevalence of Chronic Diseases

The rising incidence of chronic diseases such as diabetes, hypertension, and cardiovascular disorders is a pivotal driver for the Sustained Release Excipients Market. As the global population ages, the demand for medications that require prolonged therapeutic effects intensifies. This trend is reflected in the pharmaceutical sector, where sustained release formulations are increasingly favored for their ability to enhance patient compliance and minimize side effects. According to recent data, chronic diseases account for a substantial portion of healthcare expenditures, prompting pharmaceutical companies to invest in innovative excipients that facilitate sustained drug release. This shift not only addresses the therapeutic needs of patients but also aligns with the industry's focus on developing more effective and patient-friendly drug delivery systems.

### Rising Investment in Research and Development

The Sustained Release Excipients Market is experiencing a surge in investment directed towards research and development. Pharmaceutical companies are increasingly allocating resources to explore novel excipients that can improve drug solubility and bioavailability. This trend is underscored by the growing emphasis on developing complex formulations that cater to specific patient needs. Recent statistics suggest that R&D spending in the pharmaceutical sector has reached unprecedented levels, with a significant portion dedicated to excipient innovation. This investment not only fosters the creation of new sustained release products but also enhances the overall quality and performance of existing formulations, thereby driving market expansion.

### Growing Focus on Patient Compliance and Convenience

The increasing focus on patient compliance and convenience is a significant driver for the Sustained Release Excipients Market. Patients often prefer medications that require less frequent dosing, as this enhances adherence to treatment regimens. Sustained release formulations address this need by providing prolonged therapeutic effects, thereby reducing the burden of multiple daily doses. Market analysis reveals that products designed for improved patient convenience are gaining traction, leading to a shift in pharmaceutical strategies. As healthcare providers prioritize patient-centric approaches, the demand for excipients that facilitate sustained release mechanisms is likely to grow, further influencing market trends.

### Regulatory Support for Innovative Drug Formulations

Regulatory bodies are increasingly supportive of innovative drug formulations, which is a crucial driver for the Sustained Release Excipients Market. The establishment of streamlined approval processes for novel excipients and formulations encourages pharmaceutical companies to invest in sustained release technologies. This regulatory environment fosters innovation and facilitates the introduction of new products to the market. Data indicates that regions with proactive regulatory frameworks have seen a higher rate of new product launches, reflecting the positive impact of regulatory support on market dynamics. As companies navigate the complexities of drug development, the backing of regulatory agencies plays a vital role in promoting sustained release excipients.

### Technological Advancements in Drug Delivery Systems

Technological innovations in drug delivery systems are significantly influencing the Sustained Release Excipients Market. The integration of advanced materials and manufacturing techniques, such as 3D printing and nanotechnology, has enabled the development of more sophisticated sustained release formulations. These advancements allow for precise control over drug release profiles, enhancing the efficacy and safety of medications. Market data indicates that the adoption of these technologies is expected to grow, driven by the need for personalized medicine and targeted therapies. As pharmaceutical companies increasingly seek to differentiate their products, the demand for high-performance excipients that support sustained release mechanisms is likely to rise, further propelling market growth.

## Future Outlook

The Sustained Release Excipients Market is projected to grow at an 8.0% CAGR from 2025 to 2035, driven by increasing demand for advanced drug delivery systems and personalized medicine.

**New opportunities:**

- Development of biodegradable excipients for environmentally friendly formulations.
- Investment in R&D for novel sustained release technologies targeting chronic diseases.
- Strategic partnerships with pharmaceutical companies for co-development of specialized excipients.

By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in drug formulation innovations.

## Segment Insights

### By Product Type: Gelatin (Largest) vs. Polymers (Fastest-Growing)

In the Sustained Release Excipients Market, the product type segment displays a varied distribution of market share among 'Gelatin', 'Polymers', 'Minerals', 'Sugars', and 'Others'. Gelatin is currently the largest segment due to its extensive application in pharmaceuticals and well-established market presence. Meanwhile, Polymers are rapidly gaining traction, characterized by an increasing adoption in [drug delivery systems](https://www.marketresearchfuture.com/reports/drug-delivery-system-market-43638) that require controlled release characteristics, positioning them as a key player in the segment.

Gelatin (Dominant) vs. Polymers (Emerging)

Gelatin continues to dominate the Sustained Release Excipients Market with its advantageous properties such as biocompatibility and ease of processing, making it a preferred choice for various pharmaceutical applications. Its longstanding usage and established methods in formulation technologies enhance its position. In contrast, Polymers are emerging rapidly, driven by their versatility and innovative applications in drug delivery. Their ability to offer tailored release profiles makes them appealing for new therapeutic developments, particularly in complex formulations that require precise release mechanisms. This duality highlights the dynamic nature of the market, as traditional materials meet innovative demands.

### By Route of Administration: Oral (Largest) vs. Transdermal (Fastest-Growing)

In the Sustained Release Excipients Market, the 'Route of Administration' segment showcases a diverse distribution with Oral administration commanding the largest share due to its ease of use and patient compliance. This segment is well-established and widely favored for various therapeutic applications. Other methods like Intramuscular and Subcutaneous are also significant but hold smaller shares compared to Oral administration, while Transdermal emerges as a competitive player in the market, capturing attention for its innovative delivery mechanisms. The growth trends in this segment are driven by the increasing demand for patient-friendly drug delivery systems. Oral and Transdermal routes are gaining traction due to advancements in formulation technology and a surge in chronic disease prevalence, which drives the need for sustained release drugs. Moreover, changing consumer preferences toward non-invasive methods solidify Transdermal's position as the fastest-growing route among emerging options. Industries are focusing on improving therapeutic effectiveness and minimizing side effects, further promoting these routes of administration.

Oral (Dominant) vs. Subcutaneous (Emerging)

The Oral route of administration remains dominant in the Sustained Release Excipients Market due to its extensive usage and high patient adherence. Offering advantages such as convenience and versatility, Oral formulations encompass tablets, capsules, and liquid formulations that ensure consistent drug release. By contrast, the Subcutaneous route is rapidly emerging due to innovations in injectable sustained-release formulations that provide extended therapeutic effects with reduced dosing frequency. This growing interest reflects a shift towards targeted therapies, driven by advancements in biopharmaceuticals, making the Subcutaneous route appealing for diseases that require constant drug levels in the bloodstream, enhancing both efficacy and patient quality of life.

### By Technology: Targeted Delivery (Largest) vs. Microencapsulation (Fastest-Growing)

The Sustained Release Excipients Market is segmented into various technologies, prominently featuring Targeted Delivery, Microencapsulation, Wurster Technique, and others. Targeted Delivery holds the largest share of the segment, primarily due to its widespread application in the pharmaceuticals industry, where precision in drug delivery is crucial. Microencapsulation, on the other hand, is quickly gaining traction as the fastest-growing segment, driven by increased demand for advanced drug formulations that require controlled release mechanisms.

Technology: Targeted Delivery (Dominant) vs. Microencapsulation (Emerging)

Targeted Delivery is recognized as the dominant technology within the Sustained Release Excipients Market, widely adopted for its ability to direct drugs to specific sites in the body, enhancing therapeutic efficacy while minimizing side effects. Its established presence in various therapeutic areas positions it as a preferred choice among manufacturers. Microencapsulation, however, is emerging rapidly as a vital technology, characterized by its versatility in encapsulating active ingredients in polymers or lipids, thus improving stability, bioavailability, and controlled release profiles. This technology's adaptability to diverse applications across pharmaceuticals and nutraceuticals secures its position as an innovative alternative for future growth.

## Regional Market Share Analysis

By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American sustained release excipients market area will dominate this market. Increased R&D efforts and the presence of significant pharmaceutical businesses in the area are credited with the region's success. Over the course of the forecast period, the region is expected to become more profitable due to patent expirations and the subsequent arrival of generics.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 2: SUSTAINED RELEASE EXCIPIENTS MARKET SHARE BY REGION 2023 (USD Billion)**

Europe sustained release excipients market accounts for the second-largest market share. The primary driver of market expansion is the aging population. Furthermore, it is projected that the advancement of complex biologics and the growing need for novel drug delivery systems will drive market growth in this sector. Further, the German sustained release excipients market held the largest market share, and the UK sustained release excipients market was the fastest growing market in the European region.

The Asia-Pacific Sustained Release Excipients Market is expected to grow at the fastest CAGR from 2024 to 2032. The increased incidence of numerous infectious diseases, the quickly expanding healthcare system, and the growing need for highly potent medications are all factors contributing to this region's rise. Moreover, China’s sustained release excipients market held the largest market share, and the Indian sustained release excipients market was the fastest growing market in the Asia-Pacific region.

## Competitive Benchmarking

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the sustained release excipients market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the sustained release excipients industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global sustained release excipients industry to benefit clients and increase the market sector. In recent years, the sustained release excipients industry has offered some of the most significant advantages to medicine. Major players in the sustained release excipients market are attempting to increase market demand by investing in research and development operations, including Allergan PLC, AstraZeneca, GlaxoSmithKline PLC, Mayne Pharma Group Limited, Mylan NV, Novartis AG, Pfizer Inc., Salix Pharmaceuticals, and Sun Pharmaceutical Industries Ltd.
As a division of AbbVie Inc., Allergan Ltd. (Allergan) is a specialty pharmaceutical business that creates and distributes over-the-counter (OTC) and branded medications as well as biosimilars. The company sells goods in the following therapeutic categories: anti-infective, urology, women's health, dermatology, central nervous system, eye care, and gastroenterology. Its clients include mail-order merchants, hospitals, clinics, government agencies, and managed healthcare providers, including health maintenance organizations and other institutions. It also distributes its products to retailers, drug wholesalers, and distributors, including national retail medicine and grocery store chains.
Biopharmaceuticals are discovered, developed, produced, and marketed by Pfizer Inc. (Pfizer). The company offers solutions to address a variety of conditions, such as those related to women's health, cancer, inflammatory diseases, immune system issues, and metabolic, cardiovascular, and pain disorders. Additionally provided are sterile injectable drugs, biosimilars, contract manufacturing services, and active pharmaceutical ingredients (APIs). For over $6.7 billion, US-based pharmaceutical and biotechnology company Pfizer Inc. purchased Arena Pharmaceuticals in December 2021.
The purchase of Arena bolsters Pfizer's capabilities and expertise in immunology and inflammation, a Pfizer innovation engine that develops effective therapies for patients with debilitating immuno-inflammatory diseases in need of new treatment options.

## Recent News & Developments

- **Q2 2024: Colorcon Expands Manufacturing Capacity in India to Meet Growing Demand for Pharmaceutical Excipients** Colorcon announced the opening of a new manufacturing facility in India to increase production of pharmaceutical excipients, including those used in sustained release formulations, to support growing demand in Asia and globally.
- **Q1 2024: Lubrizol Life Science Health Launches New Sustained Release Excipient for Oral Solid Dose Formulations** Lubrizol Life Science Health introduced a new excipient designed for sustained release oral solid dose pharmaceuticals, expanding its product portfolio for controlled drug delivery applications.
- **Q2 2024: Ashland Receives FDA Approval for New Sustained Release Excipient in Extended-Release Tablets** Ashland announced that the U.S. FDA approved its latest sustained release excipient for use in extended-release tablet formulations, marking a regulatory milestone for the company.
- **Q3 2024: BASF Partners with Indian Pharma Firm to Develop Next-Generation Sustained Release Excipients** BASF entered into a partnership with an Indian pharmaceutical manufacturer to co-develop and commercialize new sustained release excipients for advanced drug delivery systems.
- **Q2 2024: Evonik Opens New Production Line for Sustained Release Excipients in Germany** Evonik inaugurated a new production line at its German facility dedicated to manufacturing excipients for sustained release drug formulations, aiming to meet rising demand in Europe.
- **Q1 2025: Roquette Appoints New Head of Global Pharmaceutical Excipients Division** Roquette announced the appointment of a new executive to lead its global pharmaceutical excipients division, with a focus on expanding the company’s sustained release excipient offerings.
- **Q2 2025: DuPont Acquires Specialty Excipients Business from Smaller European Firm** DuPont completed the acquisition of a European specialty excipients business, strengthening its portfolio in sustained release and controlled release excipient technologies.
- **Q3 2024: DFE Pharma Launches New Co-Processed Excipient for Sustained Release Tablets** DFE Pharma introduced a new co-processed excipient specifically engineered for use in sustained release tablet formulations, targeting improved performance and manufacturability.
- **Q1 2024: Gattefossé Announces Strategic Partnership with US Biotech for Sustained Release Drug Delivery** Gattefossé entered a strategic partnership with a US-based biotech company to jointly develop lipid-based excipients for sustained release drug delivery applications.
- **Q2 2025: Lonza Invests $50 Million to Expand Excipients Manufacturing for Controlled Release Drugs** Lonza announced a $50 million investment to expand its excipients manufacturing capacity, with a focus on ingredients used in controlled and sustained release pharmaceutical products.
- **Q1 2025: Merck KGaA Launches New Polymer Excipient for Extended-Release Oral Formulations** Merck KGaA introduced a new polymer excipient designed for use in extended-release oral drug formulations, enhancing its offerings in the sustained release excipients market.
- **Q3 2025: Shin-Etsu Chemical Expands Production Capacity for Hydroxypropyl Methylcellulose Used in Sustained Release Tablets** Shin-Etsu Chemical announced the expansion of its production capacity for hydroxypropyl methylcellulose, a key excipient in sustained release tablet manufacturing, to meet increasing global demand.

## Report Scope

| MARKET SIZE 2024 | 1.5(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 1.62(USD Billion) |
| MARKET SIZE 2035 | 3.498(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.0% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | BASF SE (DE), Evonik Industries AG (DE), Ashland Global Holdings Inc. (US), Dow Inc. (US), JRS Pharma (DE), Colorcon Inc. (US), FMC Corporation (US), Gattefossé (FR), Merck KGaA (DE), Shin-Etsu Chemical Co., Ltd. (JP) |
| Segments Covered | Product Type, Route of Administration, Technology, Region |
| Key Market Opportunities | Advancements in biodegradable materials enhance sustainability in the Sustained Release Excipients Market. |
| Key Market Dynamics | Rising demand for controlled drug delivery systems drives innovation in sustained release excipients and regulatory adaptations. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Sustained Release Excipients Market by 2035?**
A: The Sustained Release Excipients Market is projected to reach approximately 3.498 USD Billion by 2035.

**Q: What was the market valuation of the Sustained Release Excipients Market in 2024?**
A: In 2024, the market valuation of the Sustained Release Excipients Market was 1.5 USD Billion.

**Q: What is the expected CAGR for the Sustained Release Excipients Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Sustained Release Excipients Market during the forecast period 2025 - 2035 is 8.0%.

**Q: Which product type segment is anticipated to have the highest valuation in the Sustained Release Excipients Market?**
A: The Polymers segment is anticipated to have the highest valuation, projected to range from 0.5 to 1.2 USD Billion.

**Q: What are the key players in the Sustained Release Excipients Market?**
A: Key players in the market include BASF SE, Evonik Industries AG, Ashland Global Holdings Inc., and Dow Inc.

**Q: Which route of administration is expected to dominate the Sustained Release Excipients Market?**
A: The Oral route of administration is expected to dominate, with a projected valuation between 0.75 and 1.75 USD Billion.

**Q: What technology segment is likely to see significant growth in the Sustained Release Excipients Market?**
A: The Targeted Delivery technology segment is likely to see significant growth, with projections ranging from 0.45 to 1.05 USD Billion.

**Q: How does the valuation of the Sugars segment compare to other product types in the market?**
A: The Sugars segment is projected to have a valuation between 0.4 and 0.9 USD Billion, indicating a competitive position among product types.

**Q: What is the projected valuation range for the Intramuscular route of administration in the market?**
A: The projected valuation range for the Intramuscular route of administration is between 0.25 and 0.5 USD Billion.

**Q: What does the market data suggest about the growth potential of the Sustained Release Excipients Market?**
A: The market data suggests a robust growth potential, with an increase from 1.5 USD Billion in 2024 to 3.498 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/sustained-release-excipients-market-22077*